Interleukin (IL)-1 gene polymorphisms: Relevance of disease severity associated alleles with IL-1β and IL-1ra production in multiple sclerosis

Mediators of Inflammation

Volumn 12, Issue 2, 2003, Pages 89-94

  Schrijver, Hans M ^a   Van As, Jaco ^a   Crusius, J Bart A ^a   Dijkstra, Christien D ^a   Uitdehaag, Bernard M J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; Genetics; Interleukin 1; Interleukin 1 receptor antagonist; Multiple sclerosis

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE;

ADULT; ALLELE; ARTICLE; AUTOIMMUNE DISEASE; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DOSAGE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; IN VITRO STUDY; MALE; MULTIPLE SCLEROSIS; PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSING REMITTING MULTIPLE SCLEROSIS;

ADULT; ALLELES; FEMALE; GENE DOSAGE; HETEROZYGOTE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX; SIALOGLYCOPROTEINS;

EID: 0038127086     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/0962933031000097691     Document Type: Article

References (20)

1. Dyment DA, Sadovnick AD, Ebers GC, Sadnovich AD. Genetics of multiple sclerosis. Hum Mol Genet 1997; 6: 1693-1698.
2. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991; 88: 1445-1451.
3. Brosnan CF, Cannella B, Battistini L, Raine CS. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995; 45(6 suppl 6): S16-S21.
4. Nicoletti F, Patti F, DiMarco R, et al. Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine 1996; 8: 395-400.
5. Voltz R, Hartmann M, Spuler S, et al. Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist. J Neurol Neurosurg Psychiatry 1997; 62: 200-201.
6. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22: 396-402.
7. Tarlow JK, Blakemore AI, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91: 403-404.
8. Blakemore AI, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1380-1385.
9. Bioque G, Crusius JB, Koutroubakis I, et al. Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol 1995; 102: 379-383.
10. Schrijver HM, Crusius JB, Uitdehaag BM, et al. Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology 1999; 52: 595-599.
11. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99: 303-310.
12. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998; 28: 2598-2602.
13. de Jong BA, Huizinga TW, Bollen EL, et al. Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J Neuroimmunol 2002; 126: 172-179.
14. Yaqoob P, Newsholme EA, Calder PC. Comparison of cytokine production in cultures of whole human blood and purified mononuclear cells. Cytokine 1999; 11: 600-605.
15. Feakes R, Sawcer S, Broadley S, et al. Interleukin 1 receptor antagonist (IL-1ra) in multiple sclerosis. J Neuroimmunol 2000; 105: 96-101.
16. Kantarci OH, Atkinson EJ, Hebrink DD, McMurray CT, Weinshenker BG. Association of two variants in IL-1beta and IL-1 receptor antagonist genes with multiple sclerosis. J Neuroimmunol 2000; 106: 220-227.
17. Mann CL, Davies MB, Stevenson VL, et al. Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity. J Neuroimmunol 2002; 129: 197-204.
18. Mandrup-Poulsen T, Pociot F, Molvig J, et al. Monokine antagonism is reduced in patients with IDDM. Diabetes 1994; 43: 1242-1247.
19. Sciacca FL, Ferri C, Vandenbroeck K, et al. Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology 1999; 52: 1896-1898.
20. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain 1997; 120: 1085-1096.